1H NMR Metabolomic Signatures in Five Brain Regions of the AβPPswe Tg2576 Mouse Model of Alzheimer's Disease at Four Ages
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In the quest for biomarkers of onset and progression of Alzheimer's disease, a 1H NMR-based metabolomic study was performed on the simple single-transgenic Tg2576 mouse model. These mice develop a slow cognitive decline starting by 6 months and express amyloid plaques from 10 months of age. The metabolic profiles of extracts from five brain regions (frontal cortex, rhinal cortex, hippocampus, midbrain, and cerebellum) of Tg2576 male mice were compared to those of controls, at 1, 3, 6 and 11 months of age. The most obvious differences were due to brain regions. Age was also a discriminating parameter. Metabolic perturbations were already detected in the hippocampus and the rhinal cortex of transgenic mice as early as 1 month of age with decreased concentrations of glutamate (Glu) and N-acetylaspartate (NAA) compared to those in wild-type animals. Metabolic changes were more numerous in the hippocampus and the rhinal cortex of 3 month-old transgenic mice and involved Glu, NAA, myo-inositol, creatine, phosphocholine, and γ-aminobutyric acid (only in the hippocampus) whose concentrations decreased. A metabolic disruption characterized by an increase in the hippocampal concentrations of Glu, creatine, and taurine was detected in 6 month-old transgenic mice. At this time point, the chemical profile of the cerebellum was slightly affected. At 11 months, all the brain regions analyzed (except the frontal cortex) were metabolically altered, with mainly a marked increase in the formation of the neuroprotective metabolites creatine and taurine. Our findings demonstrate that metabolic modifications occur long before the onset of behavioral impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“Moreover, it has been shown in patients that these two regions are more altered volumetrically and pathologically than any other brain region during early-stage AD [31–33].”
BackgroundGlutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Brewer, G. J., & Wallimann, T. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741968.x · Cited by 230 · cited 1×
“In addition to its role in brain energy homeostasis, Cr has effects such as free radical scavenging, antiapoptotic action, protection against excitotoxicity, and brain osmoregulation [38–40].”
BackgroundReduced hippocampal glutamate in Alzheimer disease
Rupsingh, R., Borrie, M., Smith, M., Wells, J. L., & Bartha, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.002 · Cited by 177
Dickson, D. W. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00065-1 · Cited by 168 · cited 1×
“Indeed definitive diagnosis of AD requires postmortem examination of the brain, which must contain sufficient numbers of plaques and tangles to qualify as affected by AD [5, 6].”
BackgroundBrain Glutamate Levels Are Decreased in Alzheimer’s Disease: A Magnetic Resonance Spectroscopy Study
Fayed, N., Modrego, P. J., Rojas-Salinas, G., & Aguilar, K. (2011) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317511421780 · Cited by 128 · cited 1×
“More recently, reduced hippocampal Glu was also proposed as an indicator of mild cognitive impairment and AD [68, 69].”
BackgroundYang, D., Xie, Z., Stephenson, D., Morton, D., Hicks, C. D., Brown, T. M., Sriram, R., O'Neill, S., Raunig, D., & Bocan, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.067 · Cited by 64
Cited by
Ashraf, A., Jeandriens, J., Parkes, H. G., & So, P.-W. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101494 · Cited by 300
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Neuroimaging of mouse models of Alzheimer’s disease
Jullienne, A., Trinh, M. V., & Obenaus, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020305 · Cited by 32
Yoo, C.-H., Kim, J., Baek, H.-M., Chang, K.-A., & Choe, B.-Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065073 · Cited by 13
Metadata
- Authors
- Lalande, J., Halley, H., Balayssac, S., Gilard, V., Déjean, S., Martino, R., Francés, B., Lassalle, J.-M., & Malet-Martino, M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2014-01-07
- Volume
- 39
- Issue
- 1
- Pages
- 121-143
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W136814610
- Cited by
- 58
- References
- 11
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 1H NMR Metabolomic Signatures in Five Brain Regions of the AβPPswe Tg2576 Mouse Model of Alzheimer's Disease at Four Ages. https://app.cochat.ai/papers/10.3233/jad-130023
- The paper
- Lalande, J., Halley, H., Balayssac, S., Gilard, V., Déjean, S., Martino, R., Francés, B., Lassalle, J.-M., & Malet-Martino, M. (2014). 1H NMR Metabolomic Signatures in Five Brain Regions of the AβPPswe Tg2576 Mouse Model of Alzheimer's Disease at Four Ages. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-130023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.